Cargando…
Treatment of disseminated granuloma annulare with fumaric acid esters
BACKGROUND: Granuloma annulare is a granulomatous disease of unknown etiology. Various therapies have been tried in disseminated granuloma annulare (DGA), including corticosteroids, several variants of psoralen plus ultraviolet-A radiation, ultraviolet- A1 radiation, systemic retinoids, and dapsone,...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC101386/ https://www.ncbi.nlm.nih.gov/pubmed/11914154 |
_version_ | 1782120201382264832 |
---|---|
author | Kreuter, Alexander Gambichler, Thilo Altmeyer, Peter Brockmeyer, Norbert H |
author_facet | Kreuter, Alexander Gambichler, Thilo Altmeyer, Peter Brockmeyer, Norbert H |
author_sort | Kreuter, Alexander |
collection | PubMed |
description | BACKGROUND: Granuloma annulare is a granulomatous disease of unknown etiology. Various therapies have been tried in disseminated granuloma annulare (DGA), including corticosteroids, several variants of psoralen plus ultraviolet-A radiation, ultraviolet- A1 radiation, systemic retinoids, and dapsone, with variable success. We report a patient with recalcitrant DGA who was treated with fumaric acid esters (FAE). CASE PRESENTATION: A 40-year old Caucasian woman presented with a 25-year history of recalcitrant DGA. On both legs and the abdomen there were erythematous annular plaques. She was treated with FAE in tablet form using two formulations differing in strength (low strength tablets: 30 mg dimethylfumarate, 67 mg monoethylfumarate Ca salt, 5 mg monoethylfumarate Mg salt, 3 mg monoethylfumarate Zn salt; high strength tablets: 120 mg dimethylfumarate, 87 mg monoethylfumarate Ca salt, 5 mg monoethylfumarate Mg salt, 3 mg monoethylfumarate Zn salt). After three-month therapy, an almost complete clearance of skin lesions was achieved. With the exception of temporary lymphopenia, no adverse effects were observed. The patient remained in remission during a six-month follow up period. CONCLUSIONS: Our observation has demonstrated that FAE is a potentially beneficial therapeutic option for patients with recalcitrant DGA. However controlled trials are necessary to fully explore the efficacy, optimal dosage, and safety of FAE in the management of DGA. |
format | Text |
id | pubmed-101386 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2002 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-1013862002-04-11 Treatment of disseminated granuloma annulare with fumaric acid esters Kreuter, Alexander Gambichler, Thilo Altmeyer, Peter Brockmeyer, Norbert H BMC Dermatol Case Report BACKGROUND: Granuloma annulare is a granulomatous disease of unknown etiology. Various therapies have been tried in disseminated granuloma annulare (DGA), including corticosteroids, several variants of psoralen plus ultraviolet-A radiation, ultraviolet- A1 radiation, systemic retinoids, and dapsone, with variable success. We report a patient with recalcitrant DGA who was treated with fumaric acid esters (FAE). CASE PRESENTATION: A 40-year old Caucasian woman presented with a 25-year history of recalcitrant DGA. On both legs and the abdomen there were erythematous annular plaques. She was treated with FAE in tablet form using two formulations differing in strength (low strength tablets: 30 mg dimethylfumarate, 67 mg monoethylfumarate Ca salt, 5 mg monoethylfumarate Mg salt, 3 mg monoethylfumarate Zn salt; high strength tablets: 120 mg dimethylfumarate, 87 mg monoethylfumarate Ca salt, 5 mg monoethylfumarate Mg salt, 3 mg monoethylfumarate Zn salt). After three-month therapy, an almost complete clearance of skin lesions was achieved. With the exception of temporary lymphopenia, no adverse effects were observed. The patient remained in remission during a six-month follow up period. CONCLUSIONS: Our observation has demonstrated that FAE is a potentially beneficial therapeutic option for patients with recalcitrant DGA. However controlled trials are necessary to fully explore the efficacy, optimal dosage, and safety of FAE in the management of DGA. BioMed Central 2002-03-19 /pmc/articles/PMC101386/ /pubmed/11914154 Text en Copyright © 2002 Kreuter et al; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any purpose, provided this notice is preserved along with the article's original URL. |
spellingShingle | Case Report Kreuter, Alexander Gambichler, Thilo Altmeyer, Peter Brockmeyer, Norbert H Treatment of disseminated granuloma annulare with fumaric acid esters |
title | Treatment of disseminated granuloma annulare with fumaric acid esters |
title_full | Treatment of disseminated granuloma annulare with fumaric acid esters |
title_fullStr | Treatment of disseminated granuloma annulare with fumaric acid esters |
title_full_unstemmed | Treatment of disseminated granuloma annulare with fumaric acid esters |
title_short | Treatment of disseminated granuloma annulare with fumaric acid esters |
title_sort | treatment of disseminated granuloma annulare with fumaric acid esters |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC101386/ https://www.ncbi.nlm.nih.gov/pubmed/11914154 |
work_keys_str_mv | AT kreuteralexander treatmentofdisseminatedgranulomaannularewithfumaricacidesters AT gambichlerthilo treatmentofdisseminatedgranulomaannularewithfumaricacidesters AT altmeyerpeter treatmentofdisseminatedgranulomaannularewithfumaricacidesters AT brockmeyernorberth treatmentofdisseminatedgranulomaannularewithfumaricacidesters |